Keywords: GlaxoSmithKline, Avodart, CRL, USA, FDA, Prostate cancer

US FDA issues a CRL for GlaxoSmithKline’s sNDA on Avodart for prostate cancer risk reduction

Article | 28 January 2011

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has received a Complete Response letter from the US Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in